drugset / Trial / NCT06290102

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

NCT06290102

Phase 1 Completed 30 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The primary objectives of this study are: * To determine the pharmacokinetic (PK) profile of fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination, from a single dose of TEV-56248 (Fp and ABS multidose dry powder inhaler with e-module \[Fp/ABS eMDPI\]) in participants with asthma * To compare the PK profiles of Fp for 2 different dose strengths of TEV-56248 to that of fluticasone propionate multidose dry powder inhaler (Fp MDPI) * To compare the PK profiles of ABS between the 2 different strengths of TEV-56248 The secondary objective is: • To evaluate the safety of a single dose of TEV-56248 and a single dose of Fp MDPI

Timeline

Start
2024-05-16
Primary completion
2024-10-01
Completion
2024-10-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified Other
Subject Salbutamol Unknown Other

Indications